Cargando…

PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool

Prostate‐specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is highly overexpressed in primary and metastatic prostate cancer (PCa). This has led to the development of radiopharmaceuticals for targeted imaging and therapy under current clinical evaluation. Despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Simons, Brian W., Turtle, Norman F., Ulmert, David H., Abou, Diane S., Thorek, Daniel L. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519119/
https://www.ncbi.nlm.nih.gov/pubmed/30656716
http://dx.doi.org/10.1002/pros.23770
_version_ 1783418582553591808
author Simons, Brian W.
Turtle, Norman F.
Ulmert, David H.
Abou, Diane S.
Thorek, Daniel L. J.
author_facet Simons, Brian W.
Turtle, Norman F.
Ulmert, David H.
Abou, Diane S.
Thorek, Daniel L. J.
author_sort Simons, Brian W.
collection PubMed
description Prostate‐specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is highly overexpressed in primary and metastatic prostate cancer (PCa). This has led to the development of radiopharmaceuticals for targeted imaging and therapy under current clinical evaluation. Despite this progress, the exact biological role of the protein in prostate cancer development and progression has not been fully elucidated. This is in part because the human PSMA and mouse PSMA (mPSMA) have different patterns of anatomical expression which confound study in the most widely utilized model organisms. Most notably, mPSMA is not expressed in the healthy murine prostate. Here, we reveal that mPSMA is highly upregulated in the prostate adenocarcinoma of the spontaneous Hi‐Myc mouse model, a highly accurate and well characterized mouse model of prostate cancer development. Antibody detection and molecular imaging tools are used to confirm that mPSMA is expressed from early prostatic intraepithelial neoplasia (PIN) through adenocarcinoma.
format Online
Article
Text
id pubmed-6519119
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65191192019-05-21 PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool Simons, Brian W. Turtle, Norman F. Ulmert, David H. Abou, Diane S. Thorek, Daniel L. J. Prostate Rapid Communications Prostate‐specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is highly overexpressed in primary and metastatic prostate cancer (PCa). This has led to the development of radiopharmaceuticals for targeted imaging and therapy under current clinical evaluation. Despite this progress, the exact biological role of the protein in prostate cancer development and progression has not been fully elucidated. This is in part because the human PSMA and mouse PSMA (mPSMA) have different patterns of anatomical expression which confound study in the most widely utilized model organisms. Most notably, mPSMA is not expressed in the healthy murine prostate. Here, we reveal that mPSMA is highly upregulated in the prostate adenocarcinoma of the spontaneous Hi‐Myc mouse model, a highly accurate and well characterized mouse model of prostate cancer development. Antibody detection and molecular imaging tools are used to confirm that mPSMA is expressed from early prostatic intraepithelial neoplasia (PIN) through adenocarcinoma. John Wiley and Sons Inc. 2019-01-17 2019-05-01 /pmc/articles/PMC6519119/ /pubmed/30656716 http://dx.doi.org/10.1002/pros.23770 Text en © 2019 The Authors. The Prostate Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Rapid Communications
Simons, Brian W.
Turtle, Norman F.
Ulmert, David H.
Abou, Diane S.
Thorek, Daniel L. J.
PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool
title PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool
title_full PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool
title_fullStr PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool
title_full_unstemmed PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool
title_short PSMA expression in the Hi‐Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool
title_sort psma expression in the hi‐myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool
topic Rapid Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519119/
https://www.ncbi.nlm.nih.gov/pubmed/30656716
http://dx.doi.org/10.1002/pros.23770
work_keys_str_mv AT simonsbrianw psmaexpressioninthehimycmodelextendedutilityofarepresentativemodelofprostateadenocarcinomaforbiologicalinsightandasadrugdiscoverytool
AT turtlenormanf psmaexpressioninthehimycmodelextendedutilityofarepresentativemodelofprostateadenocarcinomaforbiologicalinsightandasadrugdiscoverytool
AT ulmertdavidh psmaexpressioninthehimycmodelextendedutilityofarepresentativemodelofprostateadenocarcinomaforbiologicalinsightandasadrugdiscoverytool
AT aboudianes psmaexpressioninthehimycmodelextendedutilityofarepresentativemodelofprostateadenocarcinomaforbiologicalinsightandasadrugdiscoverytool
AT thorekdaniellj psmaexpressioninthehimycmodelextendedutilityofarepresentativemodelofprostateadenocarcinomaforbiologicalinsightandasadrugdiscoverytool